Mitch C. Hill - 18 Jan 2021 Form 4 Insider Report for Inari Medical, Inc.

Role: Chief Financial Officer
Signature: /s/ Angela Ahmad, attorney-in-fact for Mitch C. Hill
Issuer symbol: N/A
Transactions as of: 18 Jan 2021
Net transactions value: -$571,588
Form type: 4
Filing time: 20 Jan 2022, 19:05:03 UTC
Next filing: 11 May 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NARI	Common Stock	Options Exercise	$3,428	+7,500	+11%	$0.4570^*	74,941	18 Jan 2022	Direct	F1
transaction	NARI	Common Stock	Sale	$133,202	-1,766	-2.4%	$75.43	73,175	18 Jan 2022	Direct	F1, F2
transaction	NARI	Common Stock	Sale	$213,016	-2,783	-3.8%	$76.54	70,392	18 Jan 2022	Direct	F1, F3
transaction	NARI	Common Stock	Sale	$181,843	-2,351	-3.3%	$77.35	68,041	18 Jan 2022	Direct	F1, F4
transaction	NARI	Common Stock	Sale	$46,955	-600	-0.88%	$78.26	67,788	18 Jan 2022	Direct	F1, F5, F6
holding	NARI	Common Stock						1,600	18 Jan 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NARI	Stock Options (Right to buy)	Options Exercise	$0	-7,500	-3%	$0.000000	244,477	18 Jan 2022	Common Stock	7,500	$0.4570	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2021
F2	This transaction was executed in multiple trades at prices ranging from $74.95 to $75.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	This transaction was executed in multiple trades at prices ranging from $75.96 to $76.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	This transaction was executed in multiple trades at prices ranging from $76.99 to $77.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5	This transaction was executed in multiple trades at prices ranging from $78.03 to $78.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6	Includes 347 shares acquired under the Employee Stock Purchase Plan.
F7	Options vested with respected with 25% of the underlying shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after.